Cabaletta Bio (CABA) Gains from Investment Securities (2018 - 2025)
Cabaletta Bio's quarterly Gains from Investment Securities came in at -$11.4 million in Q4 2025, down 203.93% year-on-year from $11.0 million in Q4 2024, and down 463.67% quarter-over-quarter from $3.1 million in Q3 2025.
Cabaletta Bio has reported Gains from Investment Securities for 8 years, with the latest figure at -$11.4 million in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities fell 203.93% year-over-year to -$11.4 million; the trailing twelve-month figure through Dec 2025 stood at -$985000.0 (down 104.06% YoY), and the FY2025 full-year result was $3.5 million, down 69.11% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at -$11.4 million, down from $3.1 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $13.7 million in Q4 2022, with the low at -$11.4 million in Q4 2025.
- Average Gains from Investment Securities over 5 years is $2.3 million, with a median of $2.0 million recorded in 2021.
- Year-over-year, Gains from Investment Securities sank 230.65% in 2021 and jumped 17062.96% in 2022.
- Tracing CABA's Gains from Investment Securities over 5 years: stood at -$81000.0 in 2021, then jumped by 17062.96% to $13.7 million in 2022, then sank by 104.03% to -$554000.0 in 2023, then surged by 2078.88% to $11.0 million in 2024, then tumbled by 203.93% to -$11.4 million in 2025.
- The last three Gains from Investment Securities figures came in at -$11.4 million (Q4 2025), $3.1 million (Q3 2025), and $84325.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Cabaletta Bio | 194.84 Mn | 61.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.39 Mn |
| Dec 31, 2025 | -11.39 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Jun 30, 2025 | 84,325.00 |
| Jun 30, 2025 | 84,325.00 |
| Dec 31, 2024 | 10.96 Mn |
| Dec 31, 2024 | 10.96 Mn |
| Sep 30, 2024 | 168,242.00 |
| Sep 30, 2024 | 168,242.00 |
| Jun 30, 2024 | 108,949.00 |
| Jun 30, 2024 | 108,949.00 |
| Mar 31, 2024 | 1.86 Mn |
| Mar 31, 2024 | 1.86 Mn |
| Dec 31, 2023 | -554,000.00 |
| Dec 31, 2023 | -554,000.00 |
| Sep 30, 2023 | 8.20 Mn |
| Sep 30, 2023 | 8.20 Mn |
| Jun 30, 2023 | 2.31 Mn |
| Jun 30, 2023 | 2.31 Mn |
| Mar 31, 2023 | 361,823.00 |
| Mar 31, 2023 | 361,823.00 |
| Dec 31, 2022 | 13.74 Mn |
| Dec 31, 2022 | 13.74 Mn |
| Sep 30, 2022 | 1.96 Mn |
| Sep 30, 2022 | 1.96 Mn |
| Jun 30, 2022 | 6.13 Mn |
| Jun 30, 2022 | 6.13 Mn |
| Mar 31, 2022 | 101,000.00 |
| Mar 31, 2022 | 101,000.00 |
| Dec 31, 2021 | -81,000.00 |
| Dec 31, 2021 | -81,000.00 |
| Sep 30, 2021 | 2.08 Mn |
| Sep 30, 2021 | 2.08 Mn |
| Jun 30, 2021 | 2.22 Mn |
| Jun 30, 2021 | 2.22 Mn |
| Mar 31, 2021 | 1.96 Mn |
| Mar 31, 2021 | 1.96 Mn |
| Dec 31, 2020 | 62,000.00 |
| Dec 31, 2020 | 62,000.00 |
| Sep 30, 2020 | 2.89 Mn |
| Sep 30, 2020 | 2.89 Mn |
| Jun 30, 2020 | 16,714.00 |
| Jun 30, 2020 | 16,714.00 |
| Mar 31, 2020 | 1.96 Mn |
| Mar 31, 2020 | 1.96 Mn |
| Dec 31, 2019 | 1.34 Mn |
| Dec 31, 2019 | 1.34 Mn |
| Sep 30, 2019 | 17,000.00 |
| Sep 30, 2019 | 17,000.00 |
| Dec 31, 2018 | 971,353.00 |
| Dec 31, 2018 | 971,353.00 |